ALK-Abelló A/S (AKBLF)
OTC
Closed
Aug 21, 2026
Day's Range
37.9152 wk Range
22.35Overview - AKBLF - ALK-Abelló A/S
Key Statistics
Valuation
Enterprise Value
1.10B
P/E (Trailing)
39.91
P/E (Forward)
47.39
PEG Ratio
1.59
Price / Sales (TTM)
1.23
Price / Book
8.28
EV / EBITDA
3.38
Profitability
Gross Margin
69.33%
Profit Margin
19.85%
Operating Margin
24.79%
Return on Assets
12.74%
Return on Equity
21.20%
Ownership
Shares Outstanding
221.58M
Float
132.12M
Held by Insiders
0.00%
Held by Institutions
63.94%
Price stats
Beta
0.70
50-Day Avg
39.14
200-Day Avg
36.31
Dividends
Payout Ratio
26.22%
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AKBLF - ALK-Abelló A/S
Peers - AKBLF - ALK-Abelló A/S
Peer Comparison
Compared with companies in Biotechnology listed on OTC.
Profile Summary - AKBLF - ALK-Abelló A/S
About
ALK-Abelló A/S is a Denmark-based global pharmaceutical company specializing in the development, manufacturing, and marketing of products for allergy prevention, diagnosis, and treatment. Founded in 1923 and headquartered in Hørsholm, it pioneered allergy immunotherapy, offering unique vaccination therapies in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
